Eli Lilly ( LLY 0.14%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

"For too long, investing has come with barriers. Borders. Brokers. Limitations. It’s been complicated, costly, and — for ...

Eli Lilly now expects $13.5 billion in fourth-quarter sales, roughly $400 million below the low end of its previous guidance. That includes $3.5 billion for type 2 diabetes drug Mounjaro and $1.9 ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 a share ...

Lilly sues four compounders over copies of weight-loss drugs By Reuters April 23, 202512:59 PM PDTUpdated April 23, 2025 ...

Eli Lilly LLY 0.18% revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged net income of $2.76 billion, or $3.06 ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies ...

Eli Lilly files lawsuit against Indianapolis-based weight loss company Eli Lilly and Company is filing a lawsuit against Premier Weight Loss, an Indianapolis-based med spa who Lilly says is misleading ...